Nemtabrutinib MK-1026 PHASE3
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Companies
MRK (ORIGINATOR)100%
Mechanism: BTK inhibitor
Expert: Selective covalent inhibitor of Bruton's tyrosine kinase that disrupts B-cell receptor signaling critical for CLL and MCL survival.
Everyday: Blocks a protein that B-cell cancers need to survive and grow.
Targets: ["BTK"]
Notes
Non-covalent BTK inhibitor. For CLL/SLL resistant to covalent BTKis.
Data from Supabase · Updated 2026-03-24